Pharmacogenomics and Drug Interactions
Pharmacogenomics reveals how genetic variants in drug-metabolizing enzymes, transporters, and targets convert standard doses into toxic or subtherapeutic exposures. Testing is becoming standard of care.
From One-Size-Fits-All to Precision Dosing
Pharmacogenomics (PGx) examines how inherited genetic variation affects drug response. When a patient's genotype alters enzyme activity, the impact is functionally equivalent to a permanent drug interaction — a CYP2D6 poor metabolizer behaves as if they are taking a potent CYP2D6 inhibitor at all times.
CPIC Guidelines
The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes evidence-based guidelines for genotype-guided prescribing. Key gene-drug pairs with strong evidence include:
| Gene | Drug(s) | Clinical Impact |
|---|---|---|
| CYP2D6 | Codeine, tramadol, tamoxifen | Prodrug activation failure or toxicity |
| CYP2C19 | Clopidogrel, voriconazole, PPIs | Antiplatelet failure or antifungal toxicity |
| CYP2C9 + VKORC1 | Warfarin | Bleeding or inadequate anticoagulation |
| DPYD | Fluoropyrimidines (5-FU, capecitabine) | Fatal toxicity in deficient patients |
| TPMT/NUDT15 | Thiopurines (azathioprine, 6-MP) | Severe myelosuppression |
| HLA-B*57:01 | Abacavir | Hypersensitivity reaction |
| HLA-B*15:02 | Carbamazepine | Stevens-Johnson syndrome (SE Asian ancestry) |
| UGT1A1 | Irinotecan | Severe neutropenia and diarrhea |
Gene-Drug-Drug Interactions
The most complex scenarios arise when genetic variation and drug interactions co-occur. A CYP2D6 intermediate metabolizer who takes fluoxetine (CYP2D6 inhibitor) becomes a phenotypic poor metabolizer. If this patient is also on tamoxifen, endoxifen formation is virtually eliminated.
Clinical Example: Triple Interaction
Patient on codeine for pain, paroxetine for depression, genotype CYP2D6 *1/*4 (intermediate metabolizer):
- Genetic: reduced CYP2D6 function (IM)
- Drug inhibition: paroxetine further blocks residual CYP2D6
- Result: negligible morphine formation, complete analgesic failure
Without PGx testing, the prescriber might increase the codeine dose (futile) rather than switching to a non-CYP2D6-dependent analgesic.
Pre-emptive vs. Reactive Testing
Reactive testing: ordered after an adverse event or treatment failure. Useful but delayed.
Pre-emptive testing: multi-gene panel (typically CYP2D6, CYP2C19, CYP2C9, VKORC1, DPYD, TPMT, HLA-B) performed before prescribing. Results stored in the EHR with clinical decision support alerts. Cost-effectiveness is supported by studies showing:
- 30% reduction in adverse drug reactions
- $4,000-6,000 savings per patient over 5 years in high-risk populations
- Particular value in psychiatry (antidepressant selection), cardiology (clopidogrel), and oncology (fluoropyrimidines)
Ethnic Variation in Allele Frequencies
Allele frequencies vary dramatically by ancestry:
- CYP2D6 PM: 5-10% Caucasian, 1-2% East Asian, 0-5% African
- CYP2D6 UM: 1-2% Caucasian, 0.5% East Asian, 20-30% East African/Middle Eastern
- CYP2C19 PM: 2-5% Caucasian, 12-23% East Asian
- *HLA-B15:02: 2-8% Southeast Asian, rare in Caucasians
These differences explain population-level variation in drug response and interaction severity.
Implementation Barriers
Despite strong evidence, PGx adoption faces challenges: variable insurance coverage, limited clinician training, lack of integrated CDS in many EHRs, and turnaround time for results. Initiatives like the IGNITE Network and CPIC are accelerating adoption.
Key Takeaways
- A genetic poor metabolizer phenotype is functionally equivalent to taking a potent enzyme inhibitor permanently
- CPIC provides evidence-based guidelines for over 20 gene-drug pairs
- Gene-drug-drug interactions create compounded risk that PGx testing can predict
- Pre-emptive multi-gene panels are cost-effective in high-risk populations
- Allele frequencies vary significantly by ancestry; CYP2D6 UM is common in East African populations
- DPYD testing before fluoropyrimidine chemotherapy prevents potentially fatal toxicity